Gestodene

	WikiDoc Resources for Gestodene
Articles
Most recent articles on Gestodene Most cited articles on Gestodene Review articles on Gestodene Articles on Gestodene in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Gestodene Images of Gestodene Photos of Gestodene Podcasts & MP3s on Gestodene Videos on Gestodene
Evidence Based Medicine
Cochrane Collaboration on Gestodene Bandolier on Gestodene TRIP on Gestodene
Clinical Trials
Ongoing Trials on Gestodene at Clinical Trials.gov Trial results on Gestodene Clinical Trials on Gestodene at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Gestodene NICE Guidance on Gestodene NHS PRODIGY Guidance FDA on Gestodene CDC on Gestodene
Books
Books on Gestodene
News
Gestodene in the news Be alerted to news on Gestodene News trends on Gestodene
Commentary
Blogs on Gestodene
Definitions
Definitions of Gestodene
Patient Resources / Community
Patient resources on Gestodene Discussion groups on Gestodene Patient Handouts on Gestodene Directions to Hospitals Treating Gestodene Risk calculators and risk factors for Gestodene
Healthcare Provider Resources
Symptoms of Gestodene Causes & Risk Factors for Gestodene Diagnostic studies for Gestodene Treatment of Gestodene
Continuing Medical Education (CME)
CME Programs on Gestodene
International
Gestodene en Espanol Gestodene en Francais
Business
Gestodene in the Marketplace Patents on Gestodene
Experimental / Informatics
List of terms related to Gestodene

Gestodene
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy; category	X;
Routes of; administration	oral administration
ATC code	G03AA10 (WHO) G03AB06 (WHO) (only combinations with estrogens);
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	in vitro 99% using 3H=R5020 / in vivo similar to progesterone
Elimination half-life	16 to 18 hrs.
Excretion	urinary tract mainly
Identifiers
	IUPAC name (8R,9S,10R,13S,14S,17R)-13-Ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14-decahydrocyclopenta[a]phenanthren-3-one;
CAS Number	60282-87-3 ;
PubChem CID	3033968;
DrugBank	DB06730 ;
ChemSpider	2298532 ;
UNII	1664P6E6MI;
KEGG	D04316 ;
ChEMBL	ChEMBL1213583 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C21H26O2
Molar mass	310.430 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C4\C=C3/[C@@H]([C@H]2CC[C@]1([C@@H](/C=C\[C@]1(C#C)O)[C@@H]2CC3)CC)CC4;
	InChI InChI=1S/C21H26O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,10,12-13,16-19,23H,3,5-9,11H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1 ; Key:SIGSPDASOTUPFS-XUDSTZEESA-N ;
(verify)

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Gestodene is a progestogen hormonal contraceptive. Products containing gestodene include:

Melodene-15, Mirelle, and Minesse which contain 15 mcg of ethinylestradiol and 60 mcg of gestodene;
Meliane, Sunya, Femodette, and Millinette 20/75 which contain 20 mcg of ethinylestradiol and 75 mcg of gestodene; and
Gynera, Minulet, Femoden, Femodene, Katya and Millinette 30/75 which contain 30 mcg of ethinylestradiol and 75 mcg of gestodene.^[1]

Benefits

Gestodene is androgenically neutral, meaning that contraceptive pills containing gestodene do not exhibit the androgenic side effects (e.g. acne, hirsutism, weight gain) often associated with second-generation contraceptive pills, such as those containing levonorgestrel.^[2]

The synthetic estrogen dosage in third-generation contraceptive pills (including those containing gestodene) is lower than that in second-generation oral contraceptives, reducing the likelihood of weight gain, breast tenderness and migraine.^[3]

Third-generation oral contraceptives are also suitable for use in patients with diabetes or lipid disorders because they have minimal impact on blood glucose levels and the lipid profile.^[4]

Adverse effects

Women who take oral contraceptives containing gestodene are 5.6 times as likely to develop thromboembolism than women who do not take any contraceptive pill, and 1.6 times as likely to develop thromboembolism compared to women taking oral contraceptives containing levonorgestrel.^[5]

Footnotes

↑ http://www.bayerscheringpharma.es/ebbsc/cms/es/_galleries/download/s_mujer/prospectos/MelodeneS.pdf
↑ http://dermnetnz.org/treatments/antiandrogens.html
↑ Festin (2006). "Progestogens in combined oral contraceptives for contraception". The WHO Reproductive Health Library.
↑ Cerel-Suhl (1999). "Update on Oral Contraceptive Pills". American Family Physician. 60 (7): 2073–2084.
↑ Lidegaard; et al. (2011). "Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses". BMJ. 343: 1–15. doi:10.1136/bmj.d6423. PMC 3202015. PMID 22027398.
↑ Fried, J.; Bry, T. S.; 1968, Template:US Patent.
↑ DeWinter, M. S.; Siegman, C. M.; Szpilfogel, C. A.; Chem. Ind. (London) 1959, 905.

[1] ttp://www.bayerscheringpharma.es/ebbsc/cms/es/_galleries/download/s_mujer/prospectos/MelodeneS.pdf

[2] ttp://dermnetnz.org/treatments/antiandrogens.html

[3] Festin (2006). "Progestogens in combined oral contraceptives for contraception". The WHO Reproductive Health Library.

[4] Cerel-Suhl (1999). "Update on Oral Contraceptive Pills". American Family Physician. 60 (7): 2073–2084.

[5] Lidegaard; et al. (2011). "Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses". BMJ. 343: 1–15. doi:10.1136/bmj.d6423. PMC 3202015. PMID 22027398.

[6] Fried, J.; Bry, T. S.; 1968, Template:US Patent.

[7] DeWinter, M. S.; Siegman, C. M.; Szpilfogel, C. A.; Chem. Ind. (London) 1959, 905.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Gestodene

Overview

Benefits

Adverse effects

See also

Footnotes

Navigation menu

Clinical data


AHFS/Drugs.com	International Drug Names
Pregnancy category	X
Routes of administration	oral administration
ATC code	G03AA10 (WHO) G03AB06 (WHO) (only combinations with estrogens)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	in vitro 99% using ³H=R5020 / in vivo similar to progesterone
Elimination half-life	16 to 18 hrs.
Excretion	urinary tract mainly
Identifiers
IUPAC name (8R,9S,10R,13S,14S,17R)-13-Ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14-decahydrocyclopenta[a]phenanthren-3-one
CAS Number	60282-87-3^Y
PubChem CID	3033968
DrugBank	DB06730^Y
ChemSpider	2298532^Y
UNII	1664P6E6MI
KEGG	D04316^Y
ChEMBL	ChEMBL1213583^Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₁H₂₆O₂
Molar mass	310.430 g/mol
3D model (JSmol)	Interactive image
SMILES O=C4\C=C3/[C@@H]([C@H]2CC[C@]1([C@@H](/C=C\[C@]1(C#C)O)[C@@H]2CC3)CC)CC4
InChI InChI=1S/C21H26O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,10,12-13,16-19,23H,3,5-9,11H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1^Y Key:SIGSPDASOTUPFS-XUDSTZEESA-N^Y
(verify)